Heartmate XVE destination therapy for end-stage heart failure in a patient with human immunodeficiency virus.
Cardiac dysfunction is a known predictor of survival in patients with acquired immunodeficiency syndrome. In this report, we describe a human immunodeficiency virus (HIV)-infected patient with worsening heart failure who was managed successfully for 16 months with placement of a left ventricular assist device.
Mehmood
Syed
S
Division of Cardiothoracic Surgery, Richard M. Ross Heart Hospital, The Ohio State University Medical Center, Columbus, OH 43210, USA.
Blais
Danielle
D
Martin
Stanley
S
Sai-Sudhakar
Chittoor
C
D023241:Antiretroviral Therapy, Highly Active; D002311:Cardiomyopathy, Dilated / Q000503:physiopathology / Q000628:therapy* / Q000821:virology; D017809:Fatal Outcome; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006333:Heart Failure / Q000503:physiopathology / Q000628:therapy* / Q000821:virology; D006353:Heart-Assist Devices; D006801:Humans; D008297:Male; D008875:Middle Aged; D011474:Prosthesis Design; D011788:Quality of Life; D020127:Recovery of Function; D016896:Treatment Outcome